Covered recipient · General Payments record
OLIVIA T ORTIZ
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
General Payments · PY2018–2024
$1,843.41
- Reported across 122 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $308.90 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $173.92 | 10 |
| Merck Sharp & Dohme Corporation | $60.23 | 4 |
| Astellas Pharma US Inc | $24.34 | 1 |
| Novo Nordisk AS | $18.98 | 1 |
| Lilly USA, LLC | $16.76 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.67 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.52 | 01/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159527 | CMS |
| ABBVIE INC. | $16.49 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159529 | CMS |
| ABBVIE INC. | $17.42 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159531 | CMS |
| ABBVIE INC. | $16.17 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159533 | CMS |
| ABBVIE INC. | $17.86 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159535 | CMS |
| ABBVIE INC. | $18.67 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159537 | CMS |
| ABBVIE INC. | $18.04 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159539 | CMS |
| ABBVIE INC. | $18.67 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159541 | CMS |
| ABBVIE INC. | $18.60 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159543 | CMS |
| ABBVIE INC. | $18.48 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105159545 | CMS |
| Astellas Pharma US Inc | $24.34 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139280504 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.67 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117922723 | CMS |
| Lilly USA, LLC | $16.76 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135309875 | CMS |
| Merck Sharp & Dohme LLC | $15.07 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141615498 | CMS |
| Merck Sharp & Dohme LLC | $14.64 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141615424 | CMS |
| Merck Sharp & Dohme LLC | $16.85 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141955775 | CMS |
| Merck Sharp & Dohme LLC | $13.67 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141615500 | CMS |
| Novo Nordisk Inc | $18.98 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097123332 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.